Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Discovery & Development Formulation, Ingredients, Vaccines

Goodbye, Moisture. Hello, mRNA

If you mention mRNA vaccines and therapeutics in any industry circle, you’ll be hard-pressed to find a person who doesn’t have an opinion. Many companies are exploring how they can be applied to treat a broad range of diseases – and there is a sense of understandable excitement in the air.

But it’s not all plain sailing with mRNA. Stability issues could easily hamper attempts to ensure equitable access; in some cases, these therapies require temperatures as low as -70 ℃, creating obvious limitations in how far they can be transported and where they can be stored. 

However, one team claims it is inching closer to resolving the problem. RISE – a national research institute in Sweden – is working with the Karolinska Institutet, the production unit Vecura at Karolinska University Hospital, and NorthX Biologics on new processes that would create mRNA medicines able to withstand 4 ℃ or higher. RISE’s new project, NucleoDry, will focus on “dry” mRNA vaccines.

“A dry vaccine can be one of two things. It’s either a formulation where water has been removed through freeze-drying or it can be a dry formulation,” explains Randi Nordstrӧm, Researcher in Formulation Development at RISE. “The former definition typically includes drugs that can be resuspended and injected [...] The latter includes more humble drug formats, such as oral tablets. We’re focused on the first kind. [mRNA vaccines] are highly complex products chiefly because of their lipid nanoparticle structure, which incorporates both water and mRNA.”

There are two phases to the NucleoDry project. The first phase will explore drying technologies for mRNA vaccine formulations. The second phase will see the researchers building early phase development infrastructure capable of taking an API candidate through formulation development, upscaling, GMP adaption, and early phase clinical trials.

“These ambitions will require hard work, expertise, and a bit of luck; as with all research projects, there is no guarantee of success,” says Nordstrӧm. “But the Swedish research scene is teeming with talent and we’re working with an experienced team. One of our collaborators, Matti Sällberg, a group leader at Karolinska Institute, Sweden, is working on developing mRNA strains. NorthX Biologics is well-versed in large-scale GMP manufacturing of APIs for biologics and small molecule drugs, and RISE itself has a dedicated formulation unit for the development of pharmaceutical formulations for pre-clinical and clinical work. If successful, dry mRNA vaccine formulations could make storage and handling cheaper, and increase the availability of pharmaceuticals around the world.”

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Related White Papers
Highly sensitive and robust LC-MS/MS solution for quantitation of nitrosamine impurities in metformin drug products

| Contributed by Thermo Fisher Scientific

Overcoming the challenges of nitrosamine impurities in drugs

| Contributed by Thermo Fisher Scientific

HRAM LC-MS method for the determination of nitrosamine impurities in drugs

| Contributed by Thermo Fisher Scientific

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register